Salivary Aβ_1-42 may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis.

IF 4.6 2区医学 Q1 CLINICAL NEUROLOGY

Journal of Neurology Pub Date : 2023-04-01 Epub Date: 2022-12-23 DOI:10.1007/s00415-022-11509-w

Ziqi Fan, Zheyu Li, Shuai Zhao, Yanxing Chen, Yujie Su, Guoping Peng, Benyan Luo

{"title":"Salivary Aβ1-42 may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis.","authors":"Ziqi Fan, Zheyu Li, Shuai Zhao, Yanxing Chen, Yujie Su, Guoping Peng, Benyan Luo","doi":"10.1007/s00415-022-11509-w","DOIUrl":null,"url":null,"abstract":"Objective: Alzheimer's disease (AD) is the most prevalent form of dementia among the aging population. Cumulative studies aim to find non-invasive biomarkers in the early stages of AD. Saliva can be obtained easily, and salivary biomarkers have been proven effective in detecting neurodegenerative diseases. To find effective biomarkers in saliva and to help the diagnosis of AD, we performed a meta-analysis focusing on the salivary biomarkers (β-amyloid 1-42 (Aβ1-42), total tau (t-tau), phosphorylated tau (p-tau) and acetylcholinesterase (AChE)) in AD.Methods: We conducted a systematic online search for eligible studies reporting data on salivary biomarkers reflecting Aβ1-42, t-tau, p-tau, and AChE in AD cohorts versus controls. Biomarkers' performance was assessed in a random-effects meta-analysis with the ratio of mean (RoM).Results: A total of thirteen studies were included in the meta-analysis, of them seven involved salivary Aβ1-42 (271 AD and 489 controls), five involved salivary t-tau (324 AD and 252 controls), four involved salivary p-tau (130 AD and 161 controls), and three involved salivary AChE (81 AD and 54 controls). AD showed significantly higher salivary Aβ1-42 levels than control (ROM = 1.90 (95% CI 1.28-2.81, P = 0.001), while AD and control did not differ significantly on salivary t-tau, p-tau and AChE (ROM = 0.94, 95% CI 0.67-1.31, P = 0.72; ROM = 0.91, 95% CI 0.56-1.45, P = 0.68; ROM = 0.83, 95% CI 0.24-2.88, P = 0.77; respectively).Conclusion: The pooled results provide evidence that salivary Aβ1-42 may serve as a sensitive biomarker for AD; nevertheless, larger AD cohorts are required to further confirm the sensitivity and specificity of salivary Aβ1-42 for AD diagnosis.","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"270 4","pages":"1945-1954"},"PeriodicalIF":4.6000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-022-11509-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Alzheimer's disease (AD) is the most prevalent form of dementia among the aging population. Cumulative studies aim to find non-invasive biomarkers in the early stages of AD. Saliva can be obtained easily, and salivary biomarkers have been proven effective in detecting neurodegenerative diseases. To find effective biomarkers in saliva and to help the diagnosis of AD, we performed a meta-analysis focusing on the salivary biomarkers (β-amyloid 1-42 (Aβ_1-42), total tau (t-tau), phosphorylated tau (p-tau) and acetylcholinesterase (AChE)) in AD.

Methods: We conducted a systematic online search for eligible studies reporting data on salivary biomarkers reflecting Aβ_1-42, t-tau, p-tau, and AChE in AD cohorts versus controls. Biomarkers' performance was assessed in a random-effects meta-analysis with the ratio of mean (RoM).

Results: A total of thirteen studies were included in the meta-analysis, of them seven involved salivary Aβ_1-42 (271 AD and 489 controls), five involved salivary t-tau (324 AD and 252 controls), four involved salivary p-tau (130 AD and 161 controls), and three involved salivary AChE (81 AD and 54 controls). AD showed significantly higher salivary Aβ_1-42 levels than control (ROM = 1.90 (95% CI 1.28-2.81, P = 0.001), while AD and control did not differ significantly on salivary t-tau, p-tau and AChE (ROM = 0.94, 95% CI 0.67-1.31, P = 0.72; ROM = 0.91, 95% CI 0.56-1.45, P = 0.68; ROM = 0.83, 95% CI 0.24-2.88, P = 0.77; respectively).

Conclusion: The pooled results provide evidence that salivary Aβ_1-42 may serve as a sensitive biomarker for AD; nevertheless, larger AD cohorts are required to further confirm the sensitivity and specificity of salivary Aβ_1-42 for AD diagnosis.

查看原文本刊更多论文

唾液a β1-42可能是阿尔茨海默病临床应用的快速检测生物标志物：一项荟萃分析。

目的：阿尔茨海默病（AD）是老年人群中最常见的痴呆形式。累积研究的目的是在阿尔茨海默病的早期阶段找到非侵入性的生物标志物。唾液很容易获得，唾液生物标志物已被证明在检测神经退行性疾病方面是有效的。为了寻找唾液中有效的生物标志物并帮助AD的诊断，我们对AD的唾液生物标志物(β-淀粉样蛋白1-42 (a β1-42)，总tau （t-tau)，磷酸化tau （p-tau）和乙酰胆碱酯酶（AChE））进行了荟萃分析。方法：我们对符合条件的研究进行了系统的在线搜索，报告了AD队列中反映a - β1-42、t-tau、p-tau和AChE的唾液生物标志物的数据。采用随机效应荟萃分析评估生物标志物的表现，采用均数比（RoM）。结果：meta分析共纳入13项研究，其中7项涉及唾液Aβ1-42 （271 AD， 489对照），5项涉及唾液t-tau （324 AD， 252对照），4项涉及唾液p-tau （130 AD， 161对照），3项涉及唾液AChE （81 AD， 54对照）。AD患者唾液Aβ1-42水平显著高于对照组（ROM = 1.90, 95% CI 1.28 ~ 2.81, P = 0.001），而AD患者唾液t-tau、P -tau和AChE水平与对照组无显著差异(ROM = 0.94, 95% CI 0.67 ~ 1.31, P = 0.72；Rom = 0.91, 95% ci 0.56-1.45, p = 0.68；Rom = 0.83, 95% ci 0.24-2.88, p = 0.77；分别)。结论：唾液a - β1-42可能是AD的敏感生物标志物；然而，需要更大的AD队列来进一步证实唾液Aβ1-42对AD诊断的敏感性和特异性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neurology 医学-临床神经学

CiteScore

10.00

自引率

5.00%

发文量

558

审稿时长

1 months

期刊介绍： The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field. In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials. Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.